TENAX THERAPEUTICS, INC. (TENX) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$15.5M

EPS$-0.96

Market Cap$258.8M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Christopher Giordano

CEO & Executive Director

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.

Founded: 1967
Employees: 16
Headquarters: Chapel Hill, North Carolina, United States

⚡

Core Efficiency

ROE?

-16.01%

ROA?

-14.91%

D/E Ratio?

0.07

📊

Profitability Ratios

Current Ratio?

14.56

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 29, 2026 (in 142 days)

Annual Report (10-K) — Based on filing pattern

Aug 29, 2026

Predicted10-K

Mar 10, 2026

10-KQ4 20254d after period end

Mar 10, 2026

10-KFY 202569d after period end

Nov 12, 2025

10-QQ3 20251d after period end

Aug 13, 2025

10-QQ2 20252d after period end

May 14, 2025

10-QQ1 20255d after period end

Mar 25, 2025

10-KQ4 20244d after period end

Mar 25, 2025

10-KFY 202484d after period end

Nov 13, 2024

10-QQ3 202413d after period end

Loading company sections...

TENAX THERAPEUTICS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness